Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. WST
WST logo

WST Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
238.290
Open
236.160
VWAP
236.64
Vol
168.66K
Mkt Cap
16.84B
Low
234.080
Amount
39.91M
EV/EBITDA(TTM)
20.04
Total Shares
72.02M
EV
16.26B
EV/OCF(TTM)
21.54
P/S(TTM)
5.53
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
Show More

Events Timeline

(ET)
2026-03-09
16:40:00
West Pharmaceutical CEO Eric Green Plans Retirement
select
2026-02-17 (ET)
2026-02-17
16:10:00
Board Approves $1B Share Repurchase Program
select
2026-02-12 (ET)
2026-02-12
06:20:00
Sees FY26 Revenue of $3.22B to $3.28B
select
2026-02-12
06:20:00
Sees Q1 Revenue of $770M-$790M
select
2026-02-12
06:10:00
West Reports Q4 Revenue of $805M, Exceeds Expectations
select

News

CNBC
2.0
03-10CNBC
Hims & Hers Shares Rise, BioNTech Crashes Amid Leadership Changes
  • Hims & Hers Stock Surge: Shares of Hims & Hers rose 3% after Bank of America upgraded the stock from underperform to neutral, indicating market optimism about its potential to sell Novo's Ozempic and Wegovy drugs on its platform.
  • BioNTech Shares Plummet: BioNTech's stock crashed over 20% following the announcement of its co-founders' departure to establish an independent company, alongside a reported fourth-quarter net loss of €305 million, highlighting deteriorating financial conditions.
  • SolarEdge Stock Rises: Following Bank of America's upgrade to neutral, SolarEdge shares surged nearly 10%, reflecting increased market confidence in its improved margin trajectory, revenue stability, and liquidity.
  • United Natural Foods Lowers Guidance: The grocery distributor reported second-quarter revenue of $7.95 billion, missing the $8.11 billion expected, and lowered its full-year revenue guidance to $31 billion to $31.4 billion, indicating ongoing market challenges.
NASDAQ.COM
2.0
03-10NASDAQ.COM
Centene Shares Drop 7.7%, Worst Performer in S&P 500 Today
  • Poor Stock Performance: Centene's shares fell 7.7% today, making it the worst performer in the S&P 500, reflecting market concerns about its future growth prospects, which could impact investor confidence.
  • Year-to-Date Review: Year-to-date, Centene's performance is down approximately 2.8%, indicating challenges in the competitive healthcare market, potentially leading investors to reassess their investment strategies.
  • Market Dynamics Analysis: In contrast to Centene, West Pharmaceutical Services also dropped 7.7%, while Western Digital rose 5.6%, highlighting differing market reactions to various companies, which may influence investor asset allocation decisions.
  • Investor Sentiment Fluctuation: Today's stock price volatility may raise doubts among investors regarding Centene's future performance, especially against the backdrop of multiple challenges facing the healthcare industry, potentially prompting more investors to seek other investment opportunities with greater growth potential.
NASDAQ.COM
5.0
03-10NASDAQ.COM
West Pharmaceutical CEO Eric Green Plans Retirement, Transition Expected by 2026
  • Executive Retirement Plan: West Pharmaceutical's CEO Eric Green plans to retire after a successor is found, ensuring a smooth leadership transition expected in the second half of 2026, highlighting the company's commitment to stable growth.
  • New CEO Recruitment: The company has engaged a leading executive recruiting firm to assist in finding a successor, indicating a rigorous approach to executive selection that may influence future strategic direction and market confidence.
  • Performance Guidance Reaffirmed: West Pharmaceutical reaffirmed its guidance for Q1 and full-year 2026, expecting adjusted earnings per share between $1.65 and $1.70, reflecting a year-over-year growth of 13% to 16.4%, demonstrating the company's robust market performance.
  • Sales Growth Expectations: The company anticipates Q1 2026 net sales between $770 million and $790 million, representing a year-over-year growth of 10.3% to 13.2%, which not only reflects strong market demand but also lays a solid foundation for the company's future financial health.
seekingalpha
5.0
03-09seekingalpha
West Pharmaceutical CEO Eric Green Plans Retirement After Succession
  • CEO Retirement Announcement: West Pharmaceutical Services' President and CEO Eric M. Green has informed the board of his retirement plans, expected to take effect in the second half of 2026 after a successor is appointed, which may impact the company's strategic direction and leadership stability.
  • Leadership Transition Strategy: The company has engaged an executive recruiting firm to assist in the search for a successor, indicating proactive measures to ensure a smooth leadership transition that could maintain investor confidence and market stability.
  • Financial Guidance Reaffirmation: West Pharmaceutical reaffirmed its financial guidance announced on February 12, 2026, targeting 5% to 7% organic revenue growth, reflecting confidence in accelerating high-value product (HVP) demand, which may drive future performance growth.
  • Market Reaction: Following the announcement, West Pharmaceutical's stock price rose slightly by 0.04% in after-hours trading to $248.17, indicating a cautiously optimistic market sentiment regarding the company's future developments.
PRnewswire
5.0
03-09PRnewswire
West Pharmaceutical CEO Eric Green Announces Retirement
  • Leadership Transition: Eric Green, CEO of West Pharmaceutical Services, plans to retire after a successor is appointed, ensuring a smooth leadership transition expected in the second half of 2026, highlighting the company's commitment to sustained growth.
  • Remarkable Performance: Under Green's leadership, the company doubled its sales to $3.07 billion in fiscal year 2025, achieving a total shareholder return of approximately 350%, which not only reflects strong growth but also sets a solid foundation for future leadership.
  • Innovation and Pandemic Response: During Green's tenure, West drove innovations that addressed patient needs and played a crucial role in supporting vaccine delivery during the COVID-19 pandemic, showcasing the company's importance in responding to major public health challenges.
  • Future Potential: With over 10,000 employees and 25 manufacturing facilities globally, West has the capacity to deliver over 41 billion components annually, demonstrating its strong potential to achieve long-term growth ambitions.
Newsfilter
5.0
03-09Newsfilter
West Pharmaceutical CEO Eric Green Announces Retirement Plans
  • Leadership Transition: Eric Green, CEO of West Pharmaceutical Services, plans to retire once a successor is found, ensuring a smooth transition expected in the second half of 2026, which will provide new perspectives and direction for the company's future leadership.
  • Remarkable Performance Review: Under Green's tenure, the company doubled its sales and achieved a total shareholder return of approximately 350%, reflecting strong growth during his leadership and laying a solid foundation for future strategic development.
  • Innovation and Crisis Response: Green's leadership saw the company drive innovations, particularly in supporting global vaccine delivery during the COVID-19 pandemic, showcasing West's adaptability and market impact during crises.
  • Future Outlook: With over 10,000 employees and 25 manufacturing facilities worldwide, West generated $3.07 billion in net sales in fiscal year 2025, demonstrating its leadership in high-quality injectable solutions and positioning for continued value creation.
Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
Wall Street analysts forecast WST stock price to rise
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
285.00
Averages
348.70
High
375.00
Current: 0.000
sliders
Low
285.00
Averages
348.70
High
375.00
Deutsche Bank
Buy
maintain
$310 -> $315
AI Analysis
2026-02-13
Reason
Deutsche Bank
Price Target
$310 -> $315
AI Analysis
2026-02-13
maintain
Buy
Reason
Deutsche Bank raised the firm's price target on West Pharmaceutical to $315 from $310 and keeps a Buy rating on the shares.
UBS
Dan Leonard
Buy
downgrade
$355 -> $340
2026-02-13
Reason
UBS
Dan Leonard
Price Target
$355 -> $340
2026-02-13
downgrade
Buy
Reason
UBS analyst Dan Leonard lowered the firm's price target on West Pharmaceutical to $340 from $355 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WST
Unlock Now

Valuation Metrics

The current forward P/E ratio for West Pharmaceutical Services Inc (WST.N) is 36.97, compared to its 5-year average forward P/E of 42.61. For a more detailed relative valuation and DCF analysis to assess West Pharmaceutical Services Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
42.61
Current PE
36.97
Overvalued PE
49.79
Undervalued PE
35.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
28.01
Current EV/EBITDA
23.49
Overvalued EV/EBITDA
32.98
Undervalued EV/EBITDA
23.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
7.99
Current PS
6.20
Overvalued PS
9.63
Undervalued PS
6.36

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what are the best stocks to buy today
Intellectia · 16 candidates
Market Cap: >= 10.00BRegion: USAnalyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.65T
PDD logo
PDD
PDD Holdings Inc
150.14B
QCOM logo
QCOM
Qualcomm Inc
149.82B
SMFG logo
SMFG
Sumitomo Mitsui Financial Group, Inc
148.10B
SNY logo
SNY
Sanofi SA
114.04B
CEG logo
CEG
Constellation Energy Corp
106.46B
what is the best stock to invest 6/fev
Intellectia · 31 candidates
Market Cap: >= 10.00BAnalyst Consensus: Strong Buy, Moderate BuyEps 5yr Cagr: >= 10List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
BR logo
BR
Broadridge Financial Solutions Inc
22.70B
AMZN logo
AMZN
Amazon.com Inc
2.39T
NFLX logo
NFLX
Netflix Inc
340.62B
CRM logo
CRM
Salesforce Inc
177.98B
CCI logo
CCI
Crown Castle Inc
37.61B
DELL logo
DELL
Dell Technologies Inc
76.13B
show me stocks strong buy
Intellectia · 16 candidates
Analyst Consensus: Strong BuyEps 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.64T
MSFT logo
MSFT
Microsoft Corp
3.20T
AVGO logo
AVGO
Broadcom Inc
1.57T
ABT logo
ABT
Abbott Laboratories
190.06B
INTU logo
INTU
Intuit Inc
138.84B
BSX logo
BSX
Boston Scientific Corp
138.71B
tell me which stocks are now strong buy
Intellectia · 22 candidates
Market Cap Category: large, megaAnalyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.56T
MSFT logo
MSFT
Microsoft Corp
3.46T
AVGO logo
AVGO
Broadcom Inc
1.52T
MA logo
MA
Mastercard Inc
471.21B
ABT logo
ABT
Abbott Laboratories
186.79B
UBER logo
UBER
Uber Technologies Inc
171.03B
best stocks to invest in 2026 q1
Intellectia · 21 candidates
Market Cap: >= 5.00BMarket Cap Category: large, midAnalyst Consensus: Strong Buy, Moderate BuyReturn On Equity: >= 12.0%Target Price Upside Potential: MoreAbovePriceOne Month Predict Return: >= 5.0%
Ticker
Name
Market Cap$
top bottom
MORN logo
MORN
Morningstar Inc
8.63B
KSPI logo
KSPI
Kaspi.kz AO
14.51B
MANH logo
MANH
Manhattan Associates Inc
10.01B
LOGI logo
LOGI
Logitech International SA
13.49B
TTD logo
TTD
Trade Desk Inc
17.09B
PDD logo
PDD
PDD Holdings Inc
150.37B

Whales Holding WST

L
Liontrust Asset Management PLC
Holding
WST
+8.29%
3M Return
B
Bill & Melinda Gates Foundation Asset Trust
Holding
WST
+4.84%
3M Return
E
EULAV Asset Management
Holding
WST
+1.41%
3M Return
A
Artisan Partners Limited Partnership
Holding
WST
+0.21%
3M Return
W
Walter Scott & Partners Limited
Holding
WST
-0.63%
3M Return
J
Jacobs Levy Equity Management Inc
Holding
WST
-0.91%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is West Pharmaceutical Services Inc (WST) stock price today?

The current price of WST is 237.55 USD — it has increased 1.59

What is West Pharmaceutical Services Inc (WST)'s business?

West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

What is the price predicton of WST Stock?

Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is348.70 USD with a low forecast of 285.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is West Pharmaceutical Services Inc (WST)'s revenue for the last quarter?

West Pharmaceutical Services Inc revenue for the last quarter amounts to 805.00M USD, increased 7.51

What is West Pharmaceutical Services Inc (WST)'s earnings per share (EPS) for the last quarter?

West Pharmaceutical Services Inc. EPS for the last quarter amounts to 1.82 USD, increased 2.82

How many employees does West Pharmaceutical Services Inc (WST). have?

West Pharmaceutical Services Inc (WST) has 10800 emplpoyees as of March 11 2026.

What is West Pharmaceutical Services Inc (WST) market cap?

Today WST has the market capitalization of 16.84B USD.